| 前收市價 | 1.0600 |
| 開市 | 1.0800 |
| 買盤 | 0.0000 |
| 賣出價 | 0.0000 |
| 拍板 | 16.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 0.9900 - 1.0900 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 56.85k |
InvestorPlace7 A-Rated Biotech Stocks Worth Betting on in June
Let me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers high return potential if they make significant advancements in health care. Biotech stocks represent companies that are involved in the research and development of drugs, therapies and medical devices. They include companies that work in fields such as genomics, biopharmaceuticals, bioinformatics and me
ReutersTeva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
ZacksTEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
